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Abstract
 
The coculture of cells expressing the HIV-1 envelope glycoprotein complex (Env) with cells
expressing CD4 results into cell fusion, deregulated mitosis, and subsequent cell death. Here,
we show that NF-
 
 
 
B, p53, and AP1 are activated in Env-elicited apoptosis. The nuclear factor
 
 
 
B (NF-
 
 
 
B) super repressor had an antimitotic and antiapoptotic effect and prevented the
Env-elicited phosphorylation of p53 on serine 15 and 46, as well as the activation of AP1.
Transfection with dominant-negative p53 abolished apoptosis and AP1 activation. Signs of
 
NF-
 
 
 
B and p53 activation were also detected in lymph node biopsies from HIV-1–infected
individuals. Microarrays revealed that most (85%) of the transcriptional effects of HIV-1 Env
were blocked by the p53 inhibitor pifithrin-
 
 
 
. Macroarrays led to the identification of several
Env-elicited, p53-dependent proapoptotic transcripts, in particular Puma, a proapoptotic
“BH3-only” protein from the Bcl-2 family known to activate Bax/Bak. Down modulation of
Puma by antisense oligonucleotides, as well as RNA interference of Bax and Bak, prevented
Env-induced apoptosis. HIV-1–infected primary lymphoblasts up-regulated Puma in vitro.
Moreover, circulating CD4
 
 
 
 lymphocytes from untreated, HIV-1–infected donors contained
enhanced amounts of Puma protein, and these elevated Puma levels dropped upon antiretroviral
therapy. Altogether, these data indicate that NF-
 
 
 
B and p53 cooperate as the dominant proap-
optotic transcription factors participating in HIV-1 infection.
Key words: Bax • mitochondria • NF-
 
 
 
B • Puma • Bak
 
Introduction
 
AIDS caused by HIV-1 involves the apoptotic destruction
of lymphocytes (1–3). The envelope glycoprotein complex
(Env) constitutes one of the major apoptosis inducers encoded
by the HIV-1. The soluble Env derivative gp120 can induce
apoptosis through interactions with suitable surface receptors
(3, 4). HIV-1–infected cells that express mature Env (the
gp120/gp41 complex) on the surface can also kill uninfected
cells expressing the receptor (CD4) and the coreceptor
(CXCR4 for lymphotropic Env variants, CCR5 for mono-
cytotropic Env variants). This type of bystander killing is
obtained by at least two distinct mechanisms. First, the two
interacting cells (one that expresses Env and the other that
expresses CD4 plus the coreceptor) may not fuse entirely
and simply exchange plasma membrane lipids, after a sort
of hemi-fusion process, followed by caspase-independent
death (5). Second, the two cells can undergo cytoplasmic
fusion (cytogamy), thus forming a syncytium, and undergo
nuclear fusion (karyogamy) and apoptosis (6). In syncytia,
the cyclin B1–dependent kinase 1 (Cdk1) is activated, a
process that is required for karyogamy and that culminates
in the mammalian target of rapamycin (mTOR)–mediated
phosphorylation of p53 on serine 15. The transcriptional
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activation of p53 results in the expression of proapoptotic
proteins, including Bax and cell death (7, 8). p53 and Bax
have also been found to participate in the death of HIV-1–
infected primary lymphoblasts (9, 10). Both the syncytium-
dependent and -independent Env-induced apoptosis are
suppressed by inhibitors of the gp41- and gp120-mediated
coreceptor interactions (5, 6). Moreover, both are reduced by
transfection with the Bax antagonist Bcl-2 (5, 6). In contrast,
only the syncytium-dependent cell death can be blocked by
inhibitors of Cdk1 (e.g., roscovitine), mTOR (e.g., rapamy-
cin), or p53 (e.g., cyclic pifithrin-
 
 
 
; references 7, 8).
Some of the characteristics of syncytium-induced apop-
tosis, namely aberrant cyclin B expression (11), overexpres-
sion/activation of mTOR (7), phosphorylation of p53 on
serine 15 (7, 11), and destabilization of mitochondrial
membranes (6), also affect a subset of lymph node and pe-
ripheral blood lymphocytes from HIV-1–infected donors,
correlating with viral load (7, 11–13). This suggests that the
proapoptotic signal transduction pathway, which can be
studied in Env-elicited syncytia, reflects, to some extent,
the HIV-1–stimulated cell death, as observable among cir-
culating lymphocytes. Based on this premise, we decided to
further explore the proapoptotic signal transduction path-
way participating in Env-induced syncytium-dependent
cell killing. Therefore, we analyzed Env-elicited changes in
the transcriptome and established the preponderant role of
nuclear factor 
 
 
 
B (NF-
 
 
 
B) as well as of p53 as proapoptotic
transcription factors in HIV-1–induced cell death. More-
over, we identified Puma as a proapoptotic, p53-inducible
protein that is critical for in Env-induced apoptosis. The
induction of Puma was not restricted to Env-elicited syn-
cytia but was also found in Env-triggered syncytium-inde-
pendent cell death in vitro. In addition, Puma expression
was induced in HIV-1–infected patients.
 
Materials and Methods
 
Cells and Culture Conditions for Apoptosis Induction. 
 
HeLa cells
stably transfected with the 
 
Env
 
 gene of HIV-1 LAI (HeLa Env)
and HeLa cells transfected with CD4 (HeLa CD4) were cocul-
tured at a 1:1 ratio (6) in DMEM supplemented with 10% FCS,
 
l
 
-glutamine, in the absence or presence of 1 
 
 
 
M roscovitin, 1
 
 
 
M rapamycin (Sigma-Aldrich), 10 
 
 
 
M cyclic pifithrin-
 
 
 
, 5 
 
 
 
M
MG132 (Calbiochem), the NF-
 
 
 
B inhibitory peptide SN50, or
its negative control SN50M (20 
 
 
 
M; BIOMOL Research Labo-
ratories, Inc.). HeLa/U937 cell cocultures were performed at dif-
ferent ratios (6). U937 or Jurkat cells were cultured with 500 ng/
ml recombinant gp120 protein.
 
Plasmids, Transfection, and Transcription Factor Profiling. 
 
For
transcription factor profiling, HeLa CD4 cells were transfected
with different luciferase constructs (Mercury™ pathway profiling
system from CLONTECH Laboratories, Inc.; 2 
 
 
 
g DNA) using
Lipofectamine 2000™ (2 
 
 
 
l; Invitrogen) 24 h before fusion with
HeLa Env cells (25 
 
 
 
 10
 
4
 
 in 2 ml), and the luciferase activity was
measured 24 h later using the luciferase reporter assay kit from
CLONTECH Laboratories, Inc. Transfection with pcDNA3.1
vector only, WT, dominant-negative (DN) Cdk1 mutant (14),
the I
 
 
 
B super-repressor (IKSR; a gift from L. Schmitz, Univer-
sity of Bern, Bern, Switzerland), p53 DN plasmids (p53H273; a
 
gift from T. Soussi, Institut Curie, Paris, France), or a p53-
responsive enhanced green fluorescent protein (GFP) plasmid (a
gift from K. Wiman, Karolinska Hospital, Stockholm, Sweden)
was performed 24 h before coculture of HeLa CD4 and HeLa
Env cells. The frequency of GFP-expressing cells was assessed
by cytofluorometry on a FACSVantage™ (Becton Dickinson)
equipped with a 100-
 
 
 
m nozzle, allowing for the analysis of rela-
tively large cells. Afterwards, cells were counterstained with 10
 
 
 
g/ml Hoechst 33324 (15 min), and the FACS
 
®
 
 gates were set
on syncytia (i.e., cells with a DNA content 
 
 
 
4 n) (11).
 
Immunofluorescence and Cytofluorometry. 
 
Rabbit antisera spe-
cific for p53S15P, p53S46P (Cell Signaling Technology), or the
NH
 
2
 
 terminus of Bax (N20; Santa Cruz Biotechnology, Inc.)
were used on paraformaldehyde (4% wt:vol) and picric acid–fixed
(0.19% vol:vol) cells (15) and revealed with a goat anti–rabbit
IgG conjugated to Alexa 568 (red) or Alexa 488 (green) fluoro-
chromes obtained from Molecular Probes. Cells were also stained
for the detection of the NH
 
2
 
 terminus of Bak (Ab1; Oncogene
Research Products), p53S15P (mAb), cyclin B1 (mAb; BD
Transduction Laboratories), and I
 
 
 
B
 
 
 
S32/36P (mAb; Cell Sig-
naling Technology) revealed by anti–mouse IgG Alexa conju-
gates. Cells were counterstained with Hoechst 33324, which al-
lows discernment of karyogamy and apoptotic chromatin
condensation (11).
 
Immunoblots. 
 
Samples were prepared from HeLa Env and
HeLa CD4 single cells mixed at a 1:1 ratio in lysis buffer (single
cells control) or from HeLa Env/CD4 syncytia. Protein samples
from HeLa Env and U937 mixed at different ratios were also pre-
pared and subjected to immunoblot analysis. Aliquots of protein
extracts (40 
 
 
 
g) were subjected to immunoblots using antibodies
specific for I
 
 
 
B
 
 
 
S32/36P, p53S15P, p53S46P, p53 (Cell Signal-
ing Technology), Puma (rabbit anti–human Puma antisera;
United States Biological or Orbigen; and mouse anti–human
Puma antibody; Upstate Biotechnology; all gave similar results),
 
 
 
-tubulin (mAb; Sigma-Aldrich), or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, mAb; Chemicon).
 
Microarrays, Macroarrays, and Quantitative RT-PCR. 
 
HeLa
CD4 and HeLa Env cells were labeled with CellTracker™ red or
CellTracker™ green (15 
 
 
 
M, 30 min at 37
 
 
 
C), respectively, and
washed extensively before coculture. After 18 or 36 h of cocul-
ture, in the presence or absence of 10 
 
 
 
M cyclic pifithrin-
 
 
 
 (read-
ded once upon 24 h), the cells were subjected to FACS
 
®
 
 purifica-
tion of syncytia (which are double positive) or single cells, as
described previously (11). mRNA preparations were obtained
with the RNeasy Mini kit (QIAGEN), quality-controlled with a
bioanalyzer (model 2100; Agilent Technologies), alternatively la-
beled with Cy3/Cy5 fluorochromes, mixed for pairwise compari-
sons, and hybridized to 19-k human arrays. Arrays were scanned
with a confocal laser scanner (ScanArray model 4000; Perkin-
Elmer), quantified with software (QuantArray; PerkinElmer) at
the Ontario Cancer Institute Microarray Center (http://www.
microarrays.ca), and analyzed with GeneTraffic software (Iobion
Informatics). All experiments were performed in triplicates, while
switching the Cy3/Cy5 labeling (six data points for each pair-wise
comparison) and up-regulations by 50% or down-regulations by
30% were listed. Data showing the transcriptional modification
of genes with unknown function are listed in Table SI (available
at http://www.jem.org/cgi/content/full/jem.20031216/DC1).
Macroarrays were performed using a TranSignal™ p53 target gene
array (Panomics) and quantified using the National Institutes of
Health image software. For quantitative RT-PCR, cDNAs were
synthesized from 1 
 
 
 
g of total RNA with reverse transcriptase
MuLV (Roche). The TaqMan universal PCR was performed on 
Perfettini et al.
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an ABI PRISM
 
®
 
 7000 Sequence Detection System (Applied Bio-
systems) following the manufacturer’s instructions. The following
primer sequences were used: 
 
bcl-2
 
, forward, 5
 
 
 
-CATGTGTG-
TGGAGAGCGTCAA-3
 
 
 
, reverse, 5
 
 
 
-CAGGTGTGCAGGTG-
CCG-3
 
 
 
; 
 
bax
 
 
 
 
 
, forward, 5
 
 
 
-CCAAGGTGCCGGAACTGAT-
3
 
 
 
, reverse, 5
 
 
 
-AAGTAGGAGAGGAGGCCGTCC-3
 
 
 
; 
 
bax
 
 
 
 
 
,
forward, 5
 
 
 
-CCAAGGTGCCGGAACTGAT-3
 
 
 
, reverse, 5
 
 
 
-
GAGGAGGCTTGAGGAGTCTCA-3
 
 
 
; 
 
bak
 
, forward, 5
 
 
 
-ACC-
GACGCKATGACTCAGAGTTC-3
 
 
 
, reverse, 5
 
 
 
-ACACGGC-
ACCAATTGATG-3
 
 
 
; and 
 
puma
 
 (predeveloped Taqman Assays
Reagents; www.appliedbiosystems.com).
 
Antisense Constructs and RNA Interference. 
 
HPLC-purified
antisense phosphorothioate oligonucleotides (antisense Puma, 5
 
 
 
-
CATCCTTCTCATACTTTC-3
 
 
 
; and control, CTTTCAT-
ACTCTTCCTAC-3
 
 
 
; GeneSet Oligos) (100 nM) were trans-
fected with Oligofectamine (Invitrogen) into HeLa CD4 cells
24 h before coculture with HeLa Env cells. RNA interference of
Bax and Bak expression was obtained by means of double-
stranded morpholino oligonucleotides (GeneSet Oligos) specific
for Bax (sense strand, 5
 
 
 
-rCUrgrgrArCrArgUrArArCrAUrgr-
grArgrCTT-3
 
 
 
) or Bak (sense strand, 5
 
 
 
-UrgrgUrCrCrCrAUr-
CrCUrgrArArCrgUrgTT-3
 
 
 
), transfected into both HeLa CD4
and HeLa Env cells 48 h before coculture.
 
Patients’ Samples and In Vitro Infection with HIV-1. 
 
Axillary
lymph node biopsies or peripheral blood samples were obtained
from healthy and HIV-1–infected individuals (all males, mean
 
age 
 
 
 
 36 yr), who were naive for highly active antiretroviral
therapy (HAART) with a plasma viral load 
 
 
 
20,000 copies/ml
or were receiving HAART with a viral load 
 
 
 
5,000 copies/ml.
Plasma HIV-1 RNA levels were determined by the bDNA pro-
cedure (Versant HIV RNA 3.0) according to the manufacturer’s
instructions (Bayer). None among the HIV-1
 
 
 
 patients received
interferons, glucocorticoids, was positive for hepatitis B or C, or
exhibited signs of autoimmunity. PBMCs were isolated by Ficoll/
Hypaque (Amersham Biosciences) centrifugation of heparinized
blood from either healthy donors and HIV-seropositive individu-
als and fixed with 4% paraformaldehyde in PBS, pH 7.2. Biopsies
were fixed with 10% formalin, dehydrated, and paraffin embed-
ded. Deparaffinized tissue sections and PBMCs were subjected to
immunocytochemistry with antibodies specific for p53S46P,
I
 
 
 
B
 
 
 
S32/36P, or PUMA and counterstained with hematoxylin.
PBMCs were treated with TRIzol (Invitrogen) to extract total
proteins, followed by immunoblot analysis. Alternatively, freshly
purified PBMCs were stained with anti-CD4 antibody (FITC-
labeled OKT3) and FACS
 
®
 
 sorted, followed by protein extrac-
tion. Primary CD4
 
 
 
 lymphoblasts (10 
 
 
 
 10
 
6
 
) cells (7) were in-
cubated with the HIV-1
 
LAI/IIIB
 
 strain or different clinical HIV-1
isolates (500 ng of p24; reference 16) for 4 h at 37
 
 
 
C. After wash-
ing out unabsorbed virus, cells (106 cells/ml) were cultured in
RPMI 1640 medium containing 20% FCS and 10 U/ml IL-2.
Online Supplemental Material.  The transcripts with unknown
function that are modulated by Env-dependent syncytium for-
mation, as compared with control HeLa cells, are listed in
Table SI available at http://www.jem.org/cgi/content/full/
jem.20031216/DC1.
Results
Transcription Factor Profiling of HIV-1 Env-elicited Apoptosis.
In a model culture system of syncytium-dependent cell
death, HeLa cells stably transfected with the Env gene from
HIV-1LAI/IIIb (HeLa Env) were fused by coculture with
CD4/CXCR4-expressing HeLa cells (HeLa CD4; refer-
ences 6, 7, 17, 18). Syncytium-induced transcriptional ef-
fects were monitored by transfecting each of the two cell
lines with a series of luciferase reporter gene constructs
containing promoter elements responsive to a series of dif-
ferent transcription factors. This approach revealed that,
among a panel of 12 different transcription factors, only
NF- B, p53, and AP1 were activated by the Env-depen-
dent syncytium formation (Fig. 1 A). To determine the
hierarchy among these transcription factors, cells were
cotransfected with the aforementioned luciferase reporter
constructs as well as a nonphosphorylable mutant of I B
(IKSR; reference 19) or with a DN mutant of p53
(p53H273; reference 20). Both IKSR and p53H2731 abro-
gated the increase of NF- B, p53, and AP1-dependent
transcription found in syncytia (Fig. 1 B). These data point
to an obligate cooperation between NF- B and p53, up-
stream of AP1, in Env-elicited syncytia.
NF- B Is Required for Env-elicited Mitosis and p53 Activa-
tion.  NF- B is usually considered as an antiapoptotic tran-
scription factor (21, 22). Intrigued by its putative implication
in syncytial apoptosis, we further investigated the possible
implication of NF- B in syncytial apoptosis. Cytoplasmic
fusion is followed by nuclear fusion (karyogamy) accompa-
Figure 1. Transcription factor profiling of syncytia elicited by HIV-
Env. (A) Systematic analysis of transcription factors activated in syncytia.
HeLa CD4 cells were transfected with luciferase constructs placed under
the control of the indicated transcription factor. 24 h after transfection,
cells were cultured alone (100% control value) or in the presence of HeLa
Env cells, and the expression of luciferase was monitored 24 h later. Asterisks
indicate a significant (P   0.01; Student’s t test) increase in the luciferase
activity (mean   SD; n   3). (B) Mutual relationship among p53 and
NF- B. Cells were cotransfected with luciferase expression plasmids con-
trolled by p53, NF- B, or AP1 plus empty vector (pcDNA3.1) or the
I B super-repressor (IKSR) or a DN p53 (p53H273), and the increase in
luciferase activities in syncytia (vs. single cells) was quantified. Results are
representative of three independent experiments. Asterisks indicate signif-
icant induction of luciferase constructs.p53 in HIV-1 Infection 632
nying an aberrant, cyclin B1-dependent entry into mitosis
(11, 18). This allows for the distinction of early (prekaryo-
gamic) and late (karyogamic) syncytia. A significant fraction
of prekaryogamic syncytia exhibited the phosphorylation of
I B on serine residues 32 and 36 (I BS32/36P), as detect-
able with a phosphoneoepitope-specific antibody. I BS32/
36P was found in the cytoplasm of prekaryogamic syncytia.
In karyogamic syncytia, I BS32/36P was confined to the
nucleus (Fig. 2 A). p53 was found to exhibit an activation-
associated phosphorylation pattern, both on serine 15 (Fig. 2
B, p53S15P) and serine 46 (Fig. 2 C, p53S46P), only in
karyogamic syncytia. Immunoblot analysis confirmed the
phosphorylation of I B and p53 (Fig. 2 D). Kinetic analysis
confirmed a precise order of phosphorylation events
(I BS32/36P → p53S15P → p53S46P) (Fig. 2 E).
Transfection of HeLa CD4 and HeLa Env cells with a
p53-inducible GFP construct allowed for the quantitative
assessment of p53-dependent transcriptional effects within
syncytia. p53-dependent transcription was strongly inhib-
ited by transfection with IKSR (Fig. 3 A), as well as by
pharmacological inhibition of the NF- B translocation
with SN50 (Fig. 3 B). Simultaneously, both IKSR (Fig. 3
C) and SN50 (Fig. 3 D) inhibited the emergence of karyo-
gamic syncytia, suggesting that NF- B is required for mi-
totic progression of syncytia. Indeed, NF- B inhibition
fully prevented the syncytial accumulation of cyclin B1, as
determined by quantitative immunofluorescence analysis
(Fig. 3 E). Inhibition of the Cdk1 by DN Cdk1 (Fig. 3 A)
or roscovitine (Fig. 3 B) inhibited the p53-dependent tran-
scription, while inhibiting karyogamy (Fig. 3, C and D).
Altogether, these findings indicate that NF- B is essential
for the aberrant, cyclin B1/Cdk1-mediated entry into
karyogamy that occurs upstream of p53 activation. The re-
pression of NF- B reduced the karyogamy-associated
phosphorylation of p53 (both p53S15P and p53S46P).
Moreover, transfection with DN p53 partially inhibited the
phosphorylation of I B and totally blocked its translocation
into the nucleus (Fig. 3 E). These findings point again to an
obligate cross-talk between p53 and NF- B.
I B phosphorylation was also detectable in lymph nodes
from HIV-1 carriers (but not in those from uninfected
controls), mainly among mitotic cells (Fig. 4 B). Moreover,
the phosphorylation of p53S46P was induced by HIV-1 in-
fection of primary CD4  lymphoblasts (see below) and was
Figure 2. Phosphorylation of I B  and
p53 in Env-elicited syncytia. (A–C) Repre-
sentative immunofluorescence microphoto-
graphs of prekaryogamic and karyogamic
syncytia (36 h) with antibodies specific for
I B S32/36P (A), p53S15P (A and B),
p53S46P (C), or cytochrome c (B and C).
The frequency of the indicated phosphory-
lation events was determined both among
single cells (SCs) and karyogamic (KG) or
prekaryogamic syncytia. (D) Immunoblot
confirmation of the phosphorylation of
I B S32/36P, p53S15P, and p53S46P in
syncytia. The immunodetection of GAPDH
was performed to control equal loading.
(E) Kinetic analysis of phosphorylation
events. Syncytia (obtained by coculture of
HeLa Env and HeLa CD4 cells during the
indicated interval) were subjected to immu-
nostainings as aforementioned, and the per-
centage of cells exhibiting the indicated
parameters was quantified among the total
population of syncytia.Perfettini et al. 633
detectable in lymph node biopsies from HIV-1 carriers
(Fig. 4 A). Altogether, these data extend the notion of
HIV-1–induced NF- B activation and p53 activation.
HIV-1 Env-elicited Transcriptional Effects Involve p53 and
Lead to Puma Overexpression. To further explore the im-
plication of transcription factors in Env-induced syncytial
apoptosis, microarrays were performed on HeLa Env/CD4
cocultures maintained for 18 or 36 h in the presence or ab-
sence of cyclic pifithrin- , a chemical inhibitor of p53. 40
genes of known function (Table I) and 42 genes with un-
known function (Table SI) were found to be significantly
(by a factor of  1.5 or  0.67) induced or inhibited in syn-
cytia, as compared with control cells cultured separately.
The chemical inhibitor of p53 transactivation, cyclic pi-
fithrin- , was found to prevent these changes in transcrip-
tion either at 18 or 36 h for 85% among these genes, indi-
cating that p53 is indeed the principal transcription factor,
whose activation directly or indirectly (via effects on other
transcription factors) determines the pathophysiology of
syncytial apoptosis.
Based on the fact that the microarrays used in this study
do not cover the entire transcriptome, we used a p53-spe-
cific macroarray for the identification of genes specifically
associated with syncytial apoptosis. Using this technique,
we found that p53 itself, c-Jun (whose gene product, to-
gether with c-Fos, forms AP1), the proapoptotic gene
PIG8 (also known as ei24), the proapoptotic Bcl-2 family
member Bax, as well as the proapoptotic BH3-only Bcl-2
family member Puma were up-regulated in syncytia by a
factor  2 (Fig. 5, A and B). Quantitative RT-PCR con-
Figure 3. Rules governing the activation of p53 in
Env-elicited syncytia. (A) Genetic inhibition of p53-
dependent transcription. HeLa CD4 cells were cotrans-
fected with a p53-inducible GFP construct, together
with vector only (pcDNA3.1), a dominant-negative
(DN) Cdk1 mutant, DN p53 (p53H273), or IKSR. After
24 h, the cells were either left alone (single cells) or co-
cultured with HeLa Env cells for 36 h, followed by
cytofluorometric determination of GFP. (B) Pharmaco-
logical inhibition of p53-dependent transcription. HeLa
CD4 cells were transfected with a p53-inducible GFP
construct. After 24 h, cells were cultured in the presence
of the indicated agents, in the presence or absence of
HeLa Env cells for 24 h, followed by determination of
the frequency of GFP-expression single cells or syncytia.
(C) Inhibition of karyogamy by IKSR. HeLa CD4 cells
were transfected with the indicated constructs as in A,
and the frequency of cells exhibiting nuclear fusion was
scored upon coculture with HeLa Env cells. (D) Inhibi-
tion of karyogamy by NF- B inhibitors. Syncytia were
treated with various drugs as in B, and the frequency of
karyogamic cells was scored. (E) Effect of IKSR and DN
p53 on cyclin B1, karyogamy, phosphorylation of I B
or p53, and apoptotic parameters. Syncytia were gener-
ated as in A, after transfection with pcDNA3.1 (Control),
IKSR, or DN p53, followed by immunofluorescence
detection of cyclin B1. The frequency of syncytia exhib-
iting an increase in cyclin B immunostaining was deter-
mined in three independent experiments after 24 h of
coculture. Moreover, the frequency of syncytia exhibiting
positive cytoplasmic or nuclear I BS32/36P staining,
p53S15P or p53S46P, mitochondrial cytochrome c
release, or nuclear apoptosis was determined. Asterisks
indicate significant inhibitory effects (P   0.01; paired
Student’s t test; mean   SD; n   3).
Figure 4. Phosphorylation of I B  and p53 in lymph nodes from
HIV-1 carriers. Lymph nodes from age- and sex-matched controls or un-
treated HIV-1 carriers were stained for the immunocytochemical detection
(red) of I B  (S32/36)P (A) and p53S46P (B). Nuclei are counterstained
in blue. Similar results indicating a scattered p53S46 staining and staining
of mitotic cells with I B (S32/36)P were found in three independent
asymptomatic, untreated HIV-1–infected donors with a viremia of  105
copies/ml.p53 in HIV-1 Infection 634
Table I. Classification of Modulated Genes with Known Function in Env-induced Syncytia
Time after fusion
18 h 36 h
Accession 
no. Symbol Gene function       
Cell cycle
W69443 HMG14 high-mobility group (nonhistone chromosomal) protein 14   1.5 1.54   0.06 1.73   0.11  1.5
AA1475 GAPCENA rab6 GTPase activating protein (GAP and centrosome associated)  0.67  0.67 0.61   0.01  0.67
W90163 RAMP RA-regulated nuclear matrix-associated protein   0.67  0.67 0.45   0.14  0.67
R10158 LOC51185 protein   0001/member of the ATP-dependent serine
protease (LON) family
1.58   0.08  1.5  1.5  1.5
H66120 CENPE centromere protein E (312 kD) 3.07   0.78 3.55   0.43 7.39   2.39 7.01   0.27
DNA repair
W37869 EZH1 enhancer of zeste (Drosophila melanogaster) homologue 1 0.55   0.10  0.67  0.67  0.67
Tumor suppressor/apoptosis
R19586 PLP15 proteolipid protein 1 (Pelizaeus-Merzbacher disease) 1.736   60.26  1.5 2.42   0.15 3.84   1.57
R80461 PDCD5 programmed cell death 5  1.5  1.5 1.82   0.13 2.53   0.8
H28623 CREG cellular repressor of E1A-stimulated genes  0.67  0.67 0.51   0.23  0.67
N28014 BRAP BRCA1-associated protein 0.54   0.1  0.67  0.67  0.67
R77391 RECK reversion-inducing cysteine-rich protein with kazal motifs 0.44   0.04  0.67  0.67  0.67
Receptor/growth factor
regulator
AA088248 FGFR1 fibroblast growth factor receptor 1   1.5  1.5 1.62   0.03  1.5
W38478 IGFBP7 insulin-like growth factor binding protein 7  1.5  1.5 1.6   0.07  1.5
AA046598 IGFBP1 insulin-like growth factor binding protein 1  0.67  0.67 0.63   0.05  0.67
T39448 ADRA2C adrenergic  -2C receptor 1.90   0.31 1.77   0.28 3.24   0.56 3.95   1.24
N30625 CORT cortistatin  0.67  0.67 0.6   0.1  0.67
AA151595 IFNAR2 interferon ( ,  , and  ) receptor 2 1.78   0.28  1.5  1.5  1.5
Signaling
H77460 LNK lymphocyte adaptor protein  1.5  1.5 2.46   0.56  1.5
R14326 HERC1 hect domain and RCC1 (CHC1)-like domain (RLD) 1  1.5  1.5 2.78   0.43 4.46   1.82
H18190 JAK1 Janus kinase 1   1.5  1.5 1.79   0.19 2.57   0.86
AA037843 NET-7 transmembrane 4 superfamily member (tetraspan NET-7)  0.67  0.67 0.52   0.08  0.67
H56674 CC1.3 splicing factor, coactivator of activating protein-1,
and estrogen receptors 
2.13   0.3 2.08   0.64 2.86   0.15 3.23   0.82
R17538 PABPC4 poly(A)-binding protein, cytoplasmic 4 (inducible form) 1.88   0.25 1.91   0.19 2.08   0.43 2.45   0.78
R44875 ARIP1 atrophin-1 interacting protein 1 1.99   0.33 2.34   0.4 4.58   1.19 4.99  0.56
AA044097 ZFHX1B zinc finger homeobox 1B/encoding Smad-interacting protein 1   0.67  0.67 0.48  0.16  0.67
H62028 DYRK3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3  0.67  0.67 0.40   0.35  0.67
N45598 AKAP6 A kinase (PRKA) anchor protein 6  0.67  0.67 0.60   0.03  0.67
AA135745 CAMK2G calcium/calmodulin-dependent protein kinase (CaM kinase) II   0.5   0.1  0.67  0.67  0.67
Metabolism/protein
degradation
H47026 MGAT3 mannosyl ( -1,4-)-glycoprotein  -1,4-N-acetylglucosaminyltransferase  1.5 2.32   0.17 2.31   0.43  1.5
H60458 ACOX2 acyl-coenzyme A oxidase 2, branched chain  1.5 1.62   0.03 1.63   0.07  1.5
T91335 LUC7L LUC7 (Saccharomyces cerevisiae)-like 1.72   0.05  1.5 2.43   0.31 2.67   0.55
AA099341 GBF1 Golgi-specific brefeldin A resistance factor 1 0.54   0.05  0.67  0.67  0.67
W17311 SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 1.99   0.4 2.48   0.80 4.41   0.67  1.5
AA115737 SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 0.56   0.13  0.67  0.67  0.67
N48749 FACL3 fatty-acid-coenzyme A ligase, long-chain 3 0.61   0.04  0.67  0.67  0.67
W95228 CTSG cathepsin G  1.5  1.5 4.2   1.57 5.06   0.47
W19301 GCSH glycine cleavage system protein H (aminomethyl carrier) 0.61   0.04  0.67  0.67  0.67
W79562 ATE1 arginyltransferase 1 1.72   0.33 2.08   0.22 2.36   0.21 2.79   1.03
H98809 PABPC1 poly(A)-binding protein cytoplasmic 1  0.67  0.67 0.58   0.04  0.67
R81846 FTL ferritin, light polypeptide  0.67  0.67 0.60   0.05  0.67
The list contains genes of known function from syncytia obtained after 18 or 36 h of coculture, in the presence or absence of 10  M cyclic pifithrin- . Compared with single cells,
only genes that showed an induction or inhibition of mRNA expression (by a factor of  1.5 or  0.67, respectively) were considered. Changes in mRNA expression were determined
by microarrays as described in Materials and Methods.Perfettini et al. 635
firmed the induction of Puma and Bax (and in particular the
dominant Bax-  splice variant) transcripts (Fig. 6 A), which
is consistent with the fact that syncytia overexpress Bax (7)
and Puma (Fig. 6 B) at the protein level.
Up-regulation of Puma Is Required for Syncytial Apoptosis.
Puma has been identified recently as a p53-inducible
“BH3-only” protein that can activate the proteins Bax and
Bak to adopt a proapoptotic conformation (with exposure
of the NH2 terminus), to insert into the outer mitochon-
drial membrane and to stimulate the release of cytochrome
c, leading to subsequent caspase activation and apoptosis
(23–25). Accordingly, transfection with antisense oligonu-
cleotides designed to down-regulate the expression of
Puma (Fig. 7 B, inset; reference 24) inhibited the exposure
of the NH2-termini of Bax and Bak (as detected with con-
formation-specific antibodies), the release of cytochrome c
from syncytial mitochondria (as detected by immunofluo-
rescence staining), and the apoptosis-associated chromatin
condensation (Fig. 7, A and B). Inhibition of NF- B with
IKSR (Fig. 7 C) or SN50, as well as inhibition of p53 with
cyclic pifithrin-  (Fig. 7 D) all inhibited the activation of
Bax and Bak. RNA interference of Bax or Bak, the two
Puma receptors, significantly reduced syncytial apoptosis, as
indicated by suppression of the nuclear chromatin conden-
sation and the mitochondrial cytochrome c release (Fig. 7
E). As a side observation, we found that RNA interference
of Bak prevented the exposure of the NH2 terminus of Bax
but not vice versa, suggesting a hitherto unsuspected hier-
archy among these proapoptotic proteins. Altogether, the
data suggest that Puma acts on Bax and/or Bak to kill syn-
cytia in a p53-dependent fashion.
Induction of Puma in Several Models of HIV-1 and Env-
induced Apoptosis In Vitro.  When cocultured with HeLa
Env cells, U937 cells (which lack functional p53; reference
26) do not form heterokarya, but rather undergo apoptosis
after a transient cell-to-cell interaction (5, 6). As shown in
Fig. 8 A, apoptosis correlates with the induction of Puma,
and the up-regulation of Puma is not inhibited by cyclic
pifithrin- , underscoring that Puma can be induced in a
p53-independent fashion. Similarly, different recombinant
gp120 variants (MN and 93TH975 with preference for
CXCR4; BaL and SF162 with preference for CCR5) in-
duced cell death and Puma protein expression in U937
cells (which express both CXCR4 and CCR5), correlating
with the induction of PUMA (Fig. 8 B). Transfection of
U937 cells with p53 accelerated the kinetics of gp120-
induced Puma induction at early time points when gp120
alone still had no Puma-inducing effect (Fig. 8 C). Thus,
p53-independent and -dependent pathways can cooperate
Figure 5. Identification of p53 target genes by macroarray. Labeled
cDNA from single cells or syncytia was hybridized to filters containing
p53 target genes. The signal/background ratio was determined for all
spots (A, with  -actin as an internal control) and the change in mRNA
expression was determined as described in Materials and Methods (B).
Figure 6. Up-regulation of Puma at the mRNA and protein levels.
(A) Quantitative RT-PCR was used to determine the relative abundance
of the indicated transcripts. (B) Protein blot detection of Puma expression.
Syncytia of different ages (18 or 36 h of coculture), generated after trans-
fection with vector only or a p53 DN construct, were subjected the immuno-
detection of Puma ( 21 kD), Bax, and GAPDH as a loading control.p53 in HIV-1 Infection 636
to cause Puma induction. In p53-sufficient Jurkat cells (27),
which only express CXCR4, only the R4-tropic gp120
variants induced apoptosis and Puma expression (Fig. 8 D).
This effect was strongly inhibited by cyclic pifithrin-  (Fig.
8 E). Primary CD4  lymphoblasts from healthy donors in-
fected with HIV-1LAI/IIIb also manifested the induction of
Puma, at the protein level, well after the phosphorylation
of p53 (Fig. 8 F). CD4  lymphoblasts infected with clinical
HIV-1 isolates (16) manifested the induction of Puma,
which could be detected in yet viable syncytia (Fig. 8 G).
Thus, Env and HIV-1 infection induce Puma expression in
a variety of experimental systems.
Enhanced Puma Expression in HIV-1–infected Patients.
Lymph nodes from untreated HIV-1 patients with high
HIV-1 titers ( 20,000 copies/ml) stained more positively
for Puma than did biopsies from uninfected controls (Fig. 9
A). Using immunocytochemical methods, Puma  cells
were found among all relevant (CD4 , CD8 , and
CD14 ) cells from HIV-1–infected donors with such high
HIV-1 titers, with a preference for CD4  and CD14  cells
(Fig. 9 B). Puma expression levels among the PBMCs cor-
related positively with HIV-1 titers (Fig. 9 C). The en-
hanced Puma expression could also be detected by immu-
noblotting among circulating CD4  cells from naive
(nontreated) HIV-1 patients as compared with healthy
controls or HAART-treated individuals (Fig. 9 D). More-
over, longitudinal studies revealed that Puma levels were
reduced to normal levels when patients were undergoing
successful antiretroviral therapy (Fig. 9 C), in line with the
well-established fact that antiretroviral therapy reduces the
Figure 7. Functional impact of Puma on the Bax/Bak-mediated mito-
chondrial membrane permeabilization. (A) Effect of the Puma antisense
oligonucleotide on the conformational change of Bax and Bak. Untreated
control syncytia or syncytia generated in the presence of a Puma-specific
antisense thiorate oligonucleotide were stained with antibodies specific
for the NH2 terminus of Bax (red) or Bak (green) and counterstained
with Hoechst 33324. Note that these antibodies only recognize the
active, apoptotic conformation of Bax and Bak. (B) Quantitation of the
effect of the Puma antisense oligonucleotide, as compared with a scrambled
control oligonucleotide, determined 36 h after syncytium formation. The
insert confirms effective down-regulation of Puma as determined by
immunoblot. (C) Effect of IKSR on the activation of Bax. Cells were
either transfected with vector only (pcDNA3.1) or with IKSR, 24 h before
the generation of syncytia, and the indicated parameters were assessed in
triplicate. (D) Effect of SN50 and cyclic pifithrin-  as compared with its
control (SN50M). The indicated agents were added to HeLa Env and HeLa CD4 at the beginning of coculture, and the frequency of cells exhibiting
activation of Bax or Bak, cytochrome c release and nuclear apoptosis was assessed. (E) Effect of Bax and Bak small interfering RNA (siRNA) on the
apoptosis of Env-elicited syncytia. Cells were transfected with small interfering RNA oligonucleotides 24 h before fusion, and the indicated parameters
were assessed. The inset demonstrates the impact of siRNA on Bax and Bak expression, as determined by immunoblot. This experiment was repeated
three times with similar results.Perfettini et al. 637
increased spontaneous apoptosis of circulating CD4  lym-
phocytes from HIV-1 carriers (28, 29). These data establish
that productive HIV infection is associated with the over-
expression of the apoptotic effector Puma.
Discussion
Our data strongly indicate that one of the dominant tran-
scription factors activated in Env-elicited syncytia is p53.
More than 80% of the genes whose expression level
changed did so via a p53-dependent mechanism, as indi-
cated by the fact that chemical p53 inhibition abolished this
change. Inhibition of p53 prevented the expression of sev-
eral proapoptotic genes and disabled the death program.
p53 appears to be activated through at least two phosphor-
ylation events, which are both detectable in HIV-1 carriers.
One affects serine 15 and is mediated by mTOR, whereas
the other affects serine 46. This latter phosphorylation
event is well known to enhance the apoptogenic potential
of p53 and to relay to mitochondrial apoptosis (30, 31). Al-
though the nature of the kinase acting on serine 46 (which
is not mTOR; not depicted) remains to be determined, it
appears clear that this phosphorylation event occurs down-
stream of the Cdk1-dependent karyogamy. Genetic or
pharmacological inhibition of NF- B prevented the cyclin
B-dependent Cdk1 activation, as well as the phosphoryla-
tion of p53 on both serine 15 and 46. Thus, the proapop-
totic cooperation between NF- B and p53 observed in this
particular model is likely to be indirect, via a cell cycle–
related effect of NF- B. This would be consistent with the
fact that NF- B is mostly viewed as an apoptosis-inhibiting
transcription factor (21). NF- B activation would be nec-
essary for the advancement in cell cycle, which enables
p53-dependent transcription and apoptosis, yet would have
no direct proapoptotic transcriptional effects. Indeed, there
is no indication for the induction of antiapoptotic NF- B
target genes in our system (Tables I and Table S1). In con-
trast, the p53-mediated expression of Puma appears to be
direct, at least in Env-induced syncytia (Fig. 1–6). It is im-
portant to note that Puma expression is not under the ex-
clusive control of p53, at least in transgenic mice (32), and
that p53-independent pathways may contribute to the
Env-elicited Puma expression (Fig. 8 A–C) and actually
cooperate with the p53-dependent ones (Fig. 8 C). Thus,
Figure 8. Induction of Puma by Env and
HIV-1 in vitro. (A) Induction of Puma in
U937 cells cocultured with HeLa Env cells.
U937 cells were mixed at different ratios
with HeLa Env cells just before the prepara-
tion of cell lysates for immunoblot detection
of Puma (Control) or coculture for 36 h in
the absence or presence of the p53 inhibitor
cyclic pifithrin-  (5  M). The percentage
of dead U937 cells was determined by trypan
blue exclusion. (B) Induction of Puma by
recombinant gp120 protein in U937 cells.
U937 were exposed to the indicated gp120
protein (at 500 ng/ml) and cell death,
Puma, and GAPDH expression were deter-
mined after 4 d. (C) Cooperation between
gp120 and p53 to induce Puma in U937
cells. Cells were mock transfected or trans-
fected with wild-type p53. 1 d later, the
indicated gp120 proteins were added, and
the expression of 53 and Puma were deter-
mined 48 h later. (D) Induction of Puma by
recombinant gp120 protein in Jurkat cells as
in B. (E) Effect of cyclic pifithrin- . Jurkat
cells were treated for 4 d with 500 ng/ml
gp120 protein and/or 10  M cyclic pifithrin-
 , followed by determination of Puma
expression. (F) Induction of Puma by infec-
tion of primary lymphoblasts in vitro.
CD4  lymphoblasts from a healthy donor
were infected with HIV-1LAI/IIIb for the
indicated period, and proteins (40  g/lane)
were subjected to immunoblot determination
of p53 phosphorylation and Puma expression.
(G) Puma induction in CD4  lymphoblasts
from a healthy donor infected with a clinical
HIV-1 isolate. 5 d after infection, cells were
subjected to immunohistochemical detection
of Puma. Uninfected cells served as a negative
control. Results typical for five independent
experiments are shown.p53 in HIV-1 Infection 638
different pathways (p53-dependent or -independent) may
contribute to the induction of Puma, in vivo, in the HIV-
1–infected patient. That at least part of this Puma-inducing
effect involves p53 is suggested by the fact that p53 does
manifest proapoptotic posttranscriptional modifications (in
particular, the phosphorylation of serine 46), which are de-
tectable in resident and circulating immune cells from
HIV-1 carriers.
A cornucopia of mechanisms contribute to the enhanced
apoptotic decay of T lymphocytes in HIV-1 infection.
Rather than viewing the virus-mediated and host-dependent
contribution to lymphodepletion in an exclusive fashion, it is
conceivable that proapoptotic mechanisms actually cooper-
ate in the patient (1–3). As shown here, both soluble and
membrane-bound Env can induce the expression of the
proapoptotic protein Puma, a protein that acts on mitochon-
dria to trigger apoptosis (23–25). Recently, it has also been
shown that a mutation in Vpr that reduces its apoptogenic
potential (R77Q) is found in  80% of long-term nonpro-
gressors; that is, patients with high HIV-1 titers yet normal
CD4 counts and normal levels of spontaneous apoptosis (33,
34). Vpr directly acts on mitochondria, on a molecular com-
plex formed by Bax, and on the adenine nucleotide translo-
case (33, 35), and can also elicit p53-dependent tran-
scriptional effects (36). Although the in vitro systems
characterized here were devoid of Vpr, these findings illus-
trate that the Env- and Vpr-elicited apoptotic pathways
could cooperate in stimulating p53- and mitochondrion-
mediated cell death. Such cooperative effects would be compat-
ible with previous observations indicating a reduced expres-
Figure 9. Induction of Puma in HIV-1–infected
patients. (A) Immunocytochemical localization of Puma
in lymph node biopsies of HIV-1–infected donors as
compared with a healthy control. Similar results were
obtained with three pairs of uninfected and HIV-1–
infected donors ( 105 copies/ml). (B) Frequency of
PUMA  cells among defined subsets of mononuclear
cells. Patients (n   4) and controls (n   4) with the
same clinical characteristics as in A were subjected to
two-color immunofluorescence stainings, allowing for
the determination of the percentage (mean   SD) of
cells expressing Puma among CD4  or CD8  lympho-
cytes, as well as among CD14  monocytes. (C) Corre-
lation between PUMA expression and viral titers. The
frequency of PUMA  cells was determined among
total PBMCs of 10 untreated HIV-1  patients. Each
dot represents one patient. Calculations were per-
formed following the Pearson method. (D) Expression
of Puma in purified circulating CD4  lymphocytes
from uninfected control donors, naive HIV-1–infected
donors, and HIV-1 carriers undergoing successful
HAART. (E) Longitudinal study of individual patients.
Whole PBMCs were drawn from freshly diagnosed
(untreated) patients with viral titers  105 copies/ml, as
well as several months after HAART. In these patients,
HAART led to a reduction of retroviral titers to levels
 5,000 within 4 wk. Immunoblot detection of Puma
and  -tubulin (loading control) is shown.Perfettini et al. 639
sion of Bcl-2 in rarified CD4  cells (37) and an enhanced
level of Bax protein in those CD8  cells that are undergoing
apoptosis (38). Indeed, Bcl-2 is known to be down-regu-
lated by p53 (39), whereas Bax is up-regulated (40). The
p53-induced imbalance in the precarious equilibrium of pro-
and antiapoptotic Bcl-2 relatives (which includes Puma and
Bak, as shown in Figs. 7–9) would favor the spontaneous or
activation-induced apoptosis of T lymphocytes.
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